QIR Suite vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

QIR Suite

by CASIS Cardiac Simulation & Imaging Software

EchoNext

by Pathway Labs

AI Verdict

These tools are adjacent competitors, both focusing on cardiovascular AI but with different diagnostic approaches. QIR Suite excels in detailed quantitative analysis of MR and CT images for a broad range of cardiovascular conditions, ideal for advanced imaging diagnostics. EchoNext, on the other hand, specializes in detecting hidden structural heart disease from standard ECGs, offering a more accessible and non-invasive initial screening tool.

Choose QIR Suite if…

Choose QIR Suite if your clinical practice focuses on in-depth, quantitative analysis of cardiovascular MR and CT images. This tool is ideal for specialists who require precise measurements of over 100 clinical parameters, including blood flow, pathological volumes, and myocardial strain, to support detailed diagnosis and prognosis of complex cardiovascular conditions like myocarditis, myocardial infarct, and aortic aneurysms. It's particularly well-suited for environments where dedicated hardware and comprehensive imaging analysis are paramount.

View QIR Suite →

Choose EchoNext if…

Choose EchoNext if you need an efficient, AI-powered screening tool to detect hidden structural heart disease from standard 12-lead ECGs. This tool is best for broad patient populations, from major hospitals to community practices, aiming for early identification of conditions such as heart failure, valve disease, and pulmonary hypertension, thereby guiding decisions on which patients require further echocardiography. Its accessibility through a clinical decision support platform makes it suitable for integrating into routine clinical workflows to enhance early detection efforts.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	QIR Suite	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Locally on dedicated hardware	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is deployed through the OpenEvidence clinical decision support platform, which is used by a large number of US clinicians, suggesting a potentially streamlined integration into existing workflows. QIR Suite is deployed locally on dedicated hardware, which may require more complex setup and maintenance, potentially impacting ease of use and integration. While QIR Suite mentions optimized ergonomics based on clinician feedback, EchoNext's widespread platform integration suggests broader accessibility and potentially a more seamless user experience for a larger user base.

Clinical Value

EchoNext

EchoNext has received FDA clearance for six indications, including heart failure, valve disease, and pulmonary hypertension, and has demonstrated higher accuracy than cardiologists in detecting structural heart disease from ECGs. QIR Suite is FDA cleared and CE marked, and offers quantitative analysis of MR and CT images for various cardiovascular conditions, but specific comparative accuracy data against human interpretation or the breadth of its FDA clearances are not as extensively detailed in the provided information.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with discounts and add-ons clearly outlined. QIR Suite's pricing is 'contact for pricing' with options for one-time license or subscription, which is less transparent. The clear pricing structure of EchoNext allows for easier budget planning and understanding of the total cost of ownership, providing better upfront value transparency.

Enterprise Readiness

EchoNext

EchoNext is designed for broad access, from major hospitals to community practices, and is available through the OpenEvidence platform, which is used by over half of US clinicians, indicating strong enterprise readiness and scalability. QIR Suite is deployed locally on dedicated hardware and while it has international certifications (CE, FDA, PMDA, TFDA), its enterprise deployment strategy and existing integrations are not as clearly articulated as EchoNext's.

Innovation

EchoNext

EchoNext is highlighted as the 'world's first FDA-approved AI detection tool that reads standard 12-lead ECGs to flag high-risk structural heart diseases,' and has demonstrated superior accuracy to cardiologists in detecting these conditions. QIR Suite offers advanced AI-based analysis of MR and CT images and includes features like automatic segmentation and quantification of numerous clinical parameters, but EchoNext's novel application of AI to standard ECGs for broad structural heart disease screening represents a more significant innovative leap in accessibility and early detection.

Support & Docs

Tie

Neither tool provides specific details about their customer support channels, service level agreements, or the extent of their documentation. While both are FDA cleared, which implies a certain level of quality and validation, there is insufficient information to differentiate between them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	QIR Suite	EchoNext
Tool Name	QIR Suite	EchoNext
Company	CASIS Cardiac Simulation & Imaging Software	Pathway Labs
Description	AI-based medical imaging analysis software for cardiovascular conditions, offering quantitative evaluation of MR and CT images to support diagnosis and prognosis.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	AI-based analysis of MR and CT examinations, Detection of heart regions and pathological areas, Quantification of over 100 clinical parameters, Automatic segmentation, Blood flow/velocities quantification, Pathological volumes detection and quantification, Semi-quantification of myocardial perfusion, Strain quantification	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring QIR Suite and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

QIR Suite is designed for integration into standard reading environments like PACS and can connect to HL7 servers, aiming to reduce physician workload through swift and accurate analysis. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, which is used by over 500,000 physicians, suggesting a focus on integrating its screening output into existing physician workflows at the point of care.

What are the accuracy and sensitivity of each tool in detecting cardiac conditions?

QIR Suite utilizes deep learning algorithms for functional analysis in MRI cardiac analysis, which is stated to increase accuracy and speed of results, and has demonstrated high correlation coefficients (above 0.95) and low mean differences (under 10%) when compared to predicate devices for quantitative parameters. EchoNext has shown high accuracy in detecting structural heart disease (SHD), with an AUROC of 85.2% in internal tests and 78-80% in external validation, and in studies, it achieved 77% accuracy in identifying structural heart problems from ECGs, outperforming cardiologists who achieved 64% accuracy.

For which specific cardiac specialties and conditions are these tools best suited?

QIR Suite is an AI-based medical imaging analysis software specifically for cardiovascular conditions, offering quantitative evaluation of MR and CT images to support diagnosis and prognosis. It is designed for cardiologists and radiologists and can study conditions like myocarditis, myocardial infarct, heart failure, aortic aneurysm, and hypertrophic cardiomyopathies. EchoNext is an AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, making it suitable for cardiology, family medicine, hospital medicine, and internal medicine.

What is the typical learning curve for physicians to effectively use each tool?

QIR Suite's software ergonomics have been optimized based on clinician feedback, with a focus on intuitive navigation and a simple interface to save time and allow physicians to focus on patients. While not explicitly detailing a learning curve, EchoNext's integration with the OpenEvidence platform suggests a design for broad accessibility within existing physician tools, aiming to make breakthrough detection available without extensive delays.

What kind of customer support and resources are available for physicians using these tools?

For QIR Suite, the company CASIS has a strong scientific expertise in cardiovascular imaging and pathologies, AI, and blood flow study, indicating a depth of knowledge that would likely translate to robust support. For EchoNext, Pathway Labs is dedicated to bringing rigorously validated cardiovascular AI to clinicians, and their partnership with OpenEvidence aims to get the tool into real workflows across health systems at a national scale, implying a focus on widespread adoption and support.

What audit-trail features do these tools offer to ensure accountability and track usage?

QIR Suite generates an automated report for each analysis and allows connection and storage of analyses on a PACS and HL7 server, which would facilitate tracking and auditing of analyses. While specific audit-trail features are not detailed for EchoNext, its integration into a clinical decision support platform like OpenEvidence, which is used by a large number of physicians, suggests that it would likely adhere to standards for tracking usage and supporting clinical decision-making within that platform.

How do these tools support multi-site rollouts and consistent performance across different clinical settings?

QIR Suite has been validated using MR images from patients in Europe, the USA, and India, recorded using different manufacturers and magnetic field intensities, suggesting its capability for consistent performance across diverse settings. EchoNext has demonstrated consistent performance across academic and community campuses and did not falter when training and test sites were exchanged, showing generalization across diverse patient demographics, clinical contexts, and numerous hospitals.